Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + encorafenib + cetuximab + panitumumab
- Development stage
- Unknown
- Lead developer
- Northwestern University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of hydroxychloroquine (an autophagy inhibitor), encorafenib (a BRAF inhibitor), and either cetuximab or panitumumab (EGFR inhibitors). This combination is being investigated for the treatment of BRAF V600E-mutated metastatic colorectal cancer, with the hypothesis that autophagy inhibition with hydroxychloroquine may circumvent acquired resistance to BRAF + EGFR inhibition.
02
Targets
BRAF V600EEGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on hydroxychloroquine + encorafenib + cetuximab + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + encorafenib + cetuximab + panitumumab.